Our portfolio companies are making headlines by changing the life of patients. Stay up-to-date on their latest news.
- Epics Therapeutics Initiates First-in-Human Studies with EP282, an oral Investigational Drug for the treatment of gastrointestinal inflammatory disorders and cancer
- PRISM、Roche社とGenentech社と共同研究・ライセンス契 約を締結
- Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)
- ACTICOR BIOTECH announces its projected IPO on the Euronext Growth® market in Paris
- ニュートン・バイオキャピタル、株式会社PRISM BioLabに新規投資
- Newton Biocapital invests in PRISM BioLab to support development of a unique peptide mimetic technology platform to discover new drugs for intractable diseases
- Newton Biocapital invests in EditForce to support development of a unique DNA/RNA editing platform based on PPR protein technology
- Newton Biocapital invests in NeuVasQ: EUR 20 million Series A to develop unique blood-brain barrier therapy
- Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers.
- SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
- Newton Biocapital invests in Flemish start-up DeuterOncology
- Newton Biocapital I invests in Perseus Proteomics Inc. in Japan to develop therapeutic antibodies for the treatment of blood cancers
- Sequana Medical announces positive interim data from North American pivotal alfapump® study (POSEIDON)
- Sequana Medical announces strong interim results from RED DESERT alfapump® DSR study and provides business update
- ACTICOR BIOTECH ANNOUNCES THE SUCCESS OF THE FIRST PHASE OF ITS ACTIMIS STUDY WITH GLENZOCIMAB IN PATIENTS WITH ACUTE ISCHEMIC STROKE
- ジェイファーマ株式会社 総額 17 億 4 千 6 百万円の資金調達完了
- J-Pharma Raises 1,746 million JPY in Funding
- SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 19.0 MILLION IN AN EQUITY PLACEMENT
- Sequana Medical announces first patient enrolled in RED DESERT – REpeated Dose alfapump® DSR study for Treatment of diuretic-resistant heart failure patients
- Sequana Medical appoints leading experts as Heart Failure Scientific Advisors
- Sequana Medical announces unconditional IDE approval from U.S. FDA to start alfapump® pivotal study (POSEIDON)
- SEQUANA MEDICAL announces inclusion of alfapump® in German treatment guidelines (DGVS) for complications of liver cirrhosis
- SEQUANA MEDICAL announces acceptance of late-breaking abstract of DSR therapy for volume overload in heart failure at Heart Failure 2019 Congress
- EditForce raises 870 million JPY
- エディットフォース株式会社 総額 8 億 7 千万円の資金調達完了について
- SEQUANA MEDICAL raises €27.5 million in successful Initial Public Offering
- SEQUANA MEDICAL announces the Coverage of the Base Offering of Its Initial Public Offering on Euronext Brussels
- SEQUANA MEDICAL Launches Its Initial Public Offering on Euronext Brussels
- SEQUANA MEDICAL receives Breakthrough Device designation from the FDA for its alfapump®
- 株式会社日本政策投資銀行（DBJ）日欧アーリーステージ医薬品のベンチャーキャピタル Newton Biocapital I pricaf privée SAへの出資契約を締結
- DBJ Signs Contract with Newton Biocapital I Pricaf Privee SA, a Japanese-European Venture Capital Fund for Early Stage Pharmaceuticals
- EPICS Therapeutics to Acquire Ogeda former assets, Adding Drug Discovery & Development Capabilities
- UK NICE recommends use of the alfapump® for the treatment of refractory ascites caused by cirrhosis under special arrangements
- SEQUANA MEDICAL establishes new corporate headquarters in Ghent, Belgium and raises €8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shareholders
- ACTICOR BIOTECH raises € 15.3 M in a Series B financing
- CHROMACURE S.A., a spin-off from the Université libre de Bruxelles (ULB),is launched with €17m committed equity investment to develop enhanced cancer therapies
- SYNERGIA raises €8.1 million in Series A
- ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE
Newton Biocapital invests in NeuVasQ: EUR 20 million Series A to develop unique blood-brain barrier therapy
Newton together with public and private investment partners invests in NeuVasQ for the development of blood-brain barrier pharmaceuticals based on the disruptive research of scientific founder Prof. Benoit Vanhollebeke.
NeuVasQ aims to repair neurovascular function in a range of disorders such as stroke, epilepsy, and neurodegenerative diseases like Alzheimer’s.
Brussels, Belgium, 22 June 2021 – Newton Biocapital I (“Newton”), a life sciences investment fund active in Europe and Japan focused on chronic diseases, has announced its investment in a new Walloon start-up of the ULB: NeuVasQ Biotechnologies (“NeuVasQ”). Newton is lead investor in NeuVasQ’s EUR 20 million Series A, comprised of EUR 10 million in public investments from regional and national Belgian funding agencies including SFPI-FPIM, SRIW Life Sciences, Sambrinvest and InvestSud, with a further EUR 10 million in private investments from Newton as lead investor joined by Theodorus IV, The ULB spin-offs investment fund, and business angels from Flanders and Wallonia.
A unique and new approach to addressing neurological disorders
NeuVasQ was founded based on new insights into the molecular mechanisms maintaining the integrity of the blood-brain barrier (BBB). The BBB regulates the exchange between the vascular system and central nervous system (CNS). Increased BBB permeability, due to age or injury, is involved in many neurological conditions through the leakage of harmful blood substances into the CNS. BBB dysfunction is a factor in many neurodegenerative disorders, such as Alzheimer’s, as well asmultiple acute neurological conditions like stroke and epilepsy.
Benoit Vanhollebeke, Ir. Ph.D., Professor at the ULB and NeuVasQ’s scientific founder, explains: “By precisely targeting the pathways responsible for BBB formation, we aim to restore lost functionality to the neurovasculature. NeuVasQ will further develop this unique and targeted approach which has the potential to safely improve patient lives in a wide range of neurological disorders. I am very thankful to the investors allowing this research to find its way to the patients. I am also very grateful to the FNRS, the WELBIO, the Queen Elisabeth Medical Foundation for Neurosciences, and the ERC for their support of my team’s research at the ULB.”
With its Series A funding, NeuVasQ aims to identify the most promising indications for clinical trials, focusing on a range of neurodegenerative disorders and acute neurological disorders. As part of
these exploratory studies, NeuVasQ will also consider various innovative therapeutic modalities, including gene and mRNA therapy.
Guy Heynen, MD, Partner at Newton Biocapital: “Despite the importance of the BBB, most companies targeting it have focused on circumventing its impermeability in an effort to aid drug delivery into the CNS. Through the elucidation of the signaling pathways responsible for BBB formation, NeuVasQ is instead uniquely positioned to improve BBB integrity. I hold great hope for this approach as it is based on restoring normal function to the BBB. It really has the potential to become an entirely new type of therapy in a wide range of neurological diseases and conditions.”
Alain Parthoens, Managing Partner at Newton Biocapital: “We’re pleased to be supporting NeuVasQ as the company is working to address major unmet medical needs in CNS disorders. This is an area that is of great important to Newton, as we want to aid the development of therapies for diseases where the burden to society is extremely high. We have already been contacted by pharmaceutical companies interested in NeuVasQ’s groundbreaking technology and have started our search for a CEO to lead this promising venture.”
The public investors, SFPI, SRIW Life Sciences, Sambrinvest and InvestSud, jointly commented: “We work together to strengthen the Walloon and Belgian life sciences ecosystem and have already supported multiple new ventures introducing innovative treatments targeting unmet medical needs. We're delighted to be part of NeuVasQ, at the start of this exciting journey, and we are convinced that the outcomes derived from Benoit Vanhollebeke's research will contribute to the development of a first-in-class therapy for disabling and life-threatening CNS diseases.”
Lotfi Yelles, Partner at Theodorus IV: "We are delighted to collaborate with Benoit Vanhollebeke's Laboratory of Neurovascular Signaling at ULB and support NeuVasQ Biotechnologies' ambition in developing new therapeutic options for patients suffering from neurovascular/degenerative diseases"
About NeuVasQ Biotechnologies
NeuVasQ Biotechnologies is a spin-off founded in February 2021 by the Université Libre de Bruxelles (ULB) and Prof. Benoit Vanhollebeke, a WELBIO investigator at the Laboratory of Neurovascular Signaling at the ULB Neuroscience Institute (UNI) and Professor in the ULB Department of Molecular Biology. NeuVasQ is developing pharmaceuticals to restore blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, as well as neurodegenerative diseases like Alzheimer’s. More info at www.NeuVasQ.com
About Newton Biocapital
Newton Biocapital I is a Venture Capital Firm incorporated in Belgium, focused on financing biotech and life science projects in Europe and Japan for the prevention and treatment of chronic diseases. The fund’s approach as lead investor is to support promising start-up projects as well as neglected or undervalued late-stage projects, in order to mitigate the risks and to create investor value. The leadership team consists of specialists with long-standing management and investor experience who coach bio-entrepreneurs through the development stages of their projects. Newton Biocapital’s mission is to generate substantial financial and societal value by providing innovative, breakthrough, and affordable solutions to patients. More info at
##... SRIW Life Sciences
In line with Wallonia's traditional strengths, which include research excellence combined with entrepreneurial creativity, SRIW Life Sciences contributes to the development of a truly dynamic and fertile ecosystem that generates jobs, creates value and is attractive to foreign investors.
From clinical development to market access, SRIW Life Sciences encourages and supports entrepreneurial initiatives capable of converting scientific innovation into products that meet medical needs. SRIW Life Sciences also supports the growth of more mature activities which already generate recurring income. The role of SRIW (Société Régionale d'Investissement de Wallonie) as a risk capital provider in the life sciences sector is crucial, given its capital-intensive nature and the high degree of associated risk. More info at: www.sriw.be
About Theodorus Investment Funds
Theodorus Investment Funds is an early-stage Venture Capital fund active in Belgium and Québec, with 70m€ under management. Theodorus operates since 2003 and invests mostly in early-stage ventures in life sciences and deep tech, with a focus in Belgium on spin offs from Université Libre de Bruxelles (ULB) which is Theodorus’ historical partner. More info at www.theodorus.be